Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a significant decrease in short interest during the month of March. As of March 13th, there was short interest totaling 12,677 shares, a decrease of 70.1% from the February 26th total of 42,416 shares. Based on an average daily volume of 71,894 shares, the short-interest ratio is currently 0.2 days. Currently, 1.9% of the shares of the stock are short sold.

Analyst Ratings Changes

BDRX has been the topic of a number of research analyst reports. Wall Street Zen raised Biodexa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday. Weiss Ratings restated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Biodexa Pharmaceuticals presently has an average rating of “Sell”.

Biodexa Pharmaceuticals Trading Up 4.7%

BDRX stock opened at $0.69 on Thursday. The company has a 50 day simple moving average of $1.31 and a 200 day simple moving average of $3.97. Biodexa Pharmaceuticals has a 1 year low of $0.65 and a 1 year high of $19.30.

Shares of Biodexa Pharmaceuticals are scheduled to reverse split on Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, April 3rd.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC acquired a new position in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals comprises approximately 0.6% of Sabby Management LLC’s portfolio, making the stock its 10th largest holding. Sabby Management LLC owned about 28.04% of Biodexa Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.